How much is Monte Rosa Therapeutics worth in 2026?

Monte Rosa Therapeutics has a current valuation of N/A based on their Later Stage VC (Series C) round and secondary market data.

How much funding has Monte Rosa Therapeutics raised?

Monte Rosa Therapeutics has raised N/A in total funding across 1 funding rounds.

Monte Rosa Therapeutics

Biotechnology

Monte Rosa Therapeutics valuation and funding history | Last updated: March 12, 2021 | 1 funding rounds

Current Valuation

N/A

As of March 12, 2021

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series C)

$95.0M

Last Funding

Mar 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
March 12, 2021	Later Stage VC (Series C)	$95.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Monte Rosa Therapeutics is currently valued at N/A as of March 12, 2021.

Track Monte Rosa Therapeutics Valuation Updates

Get notified when Monte Rosa Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Monte Rosa Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Monte Rosa Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Monte Rosa Therapeutics Worth in 2026?

Monte Rosa Therapeutics is a leading private company in the Biotechnology sector. Track Monte Rosa Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Monte Rosa Therapeutics Valuation is Determined

Private company valuations like Monte Rosa Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.